Developing T cell-priming immune set-point candidates against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy and clear pathogen-infected cells.
Introducing Emergex
Emergex is a clinical-stage, privately held biotechnology company headquartered in Oxfordshire, Abingdon, UK, with R&D facilities in Milton Park, UK, an operating subsidiary in Doylestown, Pennsylvania, and a GMP capable manufacturing facility in Fremont, CA, USA. Emergex is pioneering the development of a range of 100% synthetic CD8+ T cell-priming immune set-point candidates designed to harness the body’s natural cellular immune response to destroy pathogen-infected cells and to provide broad and robust immune protection for some of the world’s most urgent infectious diseases.
We work on addressing some of the world’s most impactful health threats with a growing pipeline of candidates. Emergex’s T cell-priming immune set-point candidates combine two proprietary technologies. Our lead candidates protect against infectious diseases caused by: (1) viruses, causing diseases such as Dengue Fever, Betacoronavirus, and Universal Influenza A (including pandemic influenza); as well as (2) intra-cellular bacteria, including Francisella tularensis.
Our Vision:
To positively impact global human health though the development of innovative T cell-priming product candidates for some of the world’s most immediate health threats.
Latest press releases
Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License
Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic Applicator
Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™